发表

欧盟第七框架计划GP-TCM项目报告、指南文件、专家评论、学术通讯、综述及专著

Xu Q. Therapies for systemic lupus erythematosus. Lancet 2024;404: 2162.

Liu W-B, Fermin D, Xu A-L, Kopp JB and Xu Q. Single-cell RNA sequencing data locate ALDH1A2-mediated retinoic acid synthetic pathway to glomerular parietal epithelial cells. Exp. Biol. Med. 2024; 249:10167.

Pu F, Li T, Shen C, Wang Y, Tang C, Zhang X, Yan L, Xu Q, Liu J. Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials. Ren Fail. 2024;46:2300302.

Xu Q. WHO International Standard Terminologies on Traditional Chinese Medicine: Use in Context, Creatively. Integr Med Nephrol Androl. 2023;10:e00029.

Wang X, Ma Y, Xu Q, Shikovd AN, Pozharitskayae ON, Flisyukd EV, Liu M, Li H, Vargas-Murgag L, Duez P. Flavonoids and saponins: What have we got or missed? Phytomedicine.2023; 109: 154580.

Feng Y, Chen Z-S, Xu H, Xu Q. Editorial: Medicinal plants in the treatment of gastrointestinal cancers: How can OMICS and other advanced approaches help in understanding their mechanisms of action? Front Pharmacol. 2022;13:1063915.

Shepherd A, Brunckhorst O, Ahmed K, Xu Q. Botanicals in the health and disease of the testis and male fertility: a scoping review. Phytomedicine. 2022;106:154398

Anyu AT, Zhang W, Xu Q. Cultivated cordyceps: A tale of two treasured mushrooms. Chinese Medicine and Culture 2021;4:221-227

Xu Q. The renal collecting duct rises to the defence. Nephron 2019;143:148-152.

Holden F, Amin V, Kuek D, Kopp JB, Hendry BM and Xu Q. Taming the fire of nephrotoxic botanicals. World Journal of Traditional Chinese Medicine 2019;5:151-163.

Feng Y, Yuen M-F, Xu Q, Wen X-Y, and Wang DQH. New exploration of Chinese herbal medicines in hepatology. Evid Based Complement Alternat Med. 2016;2016:3056438.

Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1:47-66

Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S21-S23.

Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20

Lu A, Zhang C, Verpoorte R, Robinson N, Xu Q. Creative and innovative good practice in traditional Chinese medicine clinical studies: Strategies for sustainable development. J Ethnopharmacol. 2014;155:1625-8.

Pelkonen O, Xu Q, Fan T-P. Why is research on herbal medicinal products important and how can we improve its quality? Journal of Traditional and Complementary Medicine 2014;4:1-7

Xu Q, Bauer R, Hendry BM, Fan TP, Zhao ZZ, Duez P, Simmonds MSJ, Witt CM, Lu AP, Robinson N, Guo DA, Hylands PJ. The Quest for Modernisation of Traditional Chinese Medicine. BMC Complement Altern Med, 2013, 13:132

Bauer R, Guo D-A, Hylands PJ, Fan TP, Xu Q. The Role of the GP-TCM Research Association to Modernization and Globalization of Traditional Chinese Medicine. In: Evandro Fei Fang, Tzi Bun Ng (Eds.) Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds. Springer Science+Business Media Dordrecht, 2013, pp 377-385. ISBN: 978-94-007-6213-8 (Print) 978-94-007-6214-5 (Online)

Xu Q, Qu F, Pelkonen O. Network Pharmacology and Traditional Chinese Medicine. In Sakagami H, ed. Alternative Medicine. ISBN 978-953-51-0903-7, Intech, 2012; pp277-297.

Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P. Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol. 2012;140:469-475

Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J, Hylands PJ. Omic techniques in systems biology approaches to traditional Chinese medicine research: Present and future. J Ethnopharmacol. 2012;140:535-544

Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T, Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM, Cheng YC, Xu Q. Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities. J Ethnopharmacol. 2012;140:458-468

Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q, Fan TP. Omics and its potential impact on R&D and regulation of complex herbal products. J Ethnopharmacol. 2012;140:587-593

Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos Centenera G, Kumari R, Xu Q, Cheng X, Watson S, Lucio Cazaña FJ. MEDLINE-based assessment of animal studies on Chinese herbal medicine. J Ethnopharmacol. 2012;140:545-549

Xu Q and Bauer R, co-eds. The GP-TCM Special Issue, Journal of Ethnopharmacology 2012; volume 140, issue 3.

Xu Q, Wong YF, Qu S, Kong Q, Zhang XL, Liang XM, Hu Q, Noor M, Hendry BM. Knowledge-based discovery of anti-fibrotic and pro-fibrotic activities from Chinese materia medica. In Kuang X, ed. Recent Advances in Theories and Practice of Chinese Medicine, Intech, 2012, pp337-352. (Book chapter reporting original data)

Uzuner H, Fan T-P, Dias A, Guo D-A, El-Nezami HS, Xu Q. Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med. 2010;5:42.

胡秦, 江丹, 徐启河. 体外纤维化模型与中草药抗纤维化活性的再认识. 牛建昭，贲长恩主编.  器官纤维化基础及中医药防治.人民卫生出版社. 2008, pp678-pp682.

同行评议的原始研究报告:

Zhuo F-F, Guo Q, Zheng Y-Z, Liu T-T, Yang Z, Xu Q-H, Jiang Y, Liu D, Tu P-F, Zeng K-W. Photoaffinity labelling-based chemoproteomic strategy reveals RBBP4 as a cellular target of protopanaxadiol against colorectal cancer cells. ChemBioChem2022; e202200038.

Zhou S, Yin X, Yuan J, Liang Z, Song J, Li Y, Peng C, Zhao ZZ, Hylands PJ and Xu Q. Antifibrotic activities of Scutellariae Radix extracts and flavonoids: comparative proteomics reveals distinct and shared mechanisms. Phytomedicine. 2022;100:154049.

Chen X, Ma J, He Y, Xue J, Song Z, Xu Q, Lin G. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats. Phytomedicine 2021;89:153595.

Zhou S, Yin X, Mayr M, Noor M, Hylands PJ and Xu Q. Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts. Sci Rep 2020;10:19054

Papadimitriou A, Romagnani P, Angelotti ML, Noor M, Corcoran J, Raby K, Wilson PD, Li J, Fraser D, Piedagnel R, Hendry BM and Xu Q. Collecting duct cells show differential retinoic acid responses to acute versus chronic kidney injury stimuli. Sci Rep 2020;10:16683.

Zhang Y, Sun L, Zhou S, Xu Q, Xu Q, Liu D, Liu L, Hu R, Quan S, Xing G. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy. Kidney Blood Press Res. 2018 Apr 23;43(2):639-650

Zhang Y, Yan X; Zhao T, Xu Q; Peng Q; Hu R; Quan S; Zhou Y, Xing G. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates IgA nephropathy in mice. Clin Exp Immunol. 2017;189:60-70.

Wang N, Xu Q, Tan HY, Hong M, Sha L, Yuen M-F and Feng Y. Berberine inhibition of fibrogenesis in a rat model of liver fibrosis and in hepatic stellate cells. Evid Based Complement Alternat Med. 2016;2016:8762345.

Zeng L, Wang G, Ummarino D, Margariti A, Xu Q, Xiao Q, Wang W, Zhang Z, Yin X, Mayr M, Cockerill G, Li JY, Chien S, Hu Y, Xu Q. Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal transition through transforming growth factor β2. J Biol Chem. 2013;288:31853-66.

Rankin AC, Hendry BM, Corcoran J, Xu Q. An in vitro model for the profibrotic effects of retinoids: Mechanisms of action. Br J Pharmacol. 2013;170:1177-89

Wong YF, Wilson PD, Unwin RJ, Norman JT, Arno M, Hendry BM, Xu Q. Retinoic acid receptor-dependent, cell-autonomous, endogenous retinoic acid signalling and its target genes in mouse collecting duct cells. PloS One 2012, 7: e45725.

  Wong YF, Kopp JB, Roberts C, Scambler PJ, Abe Y, Rankin AC, Dutt N, Hendry BM, Xu Q. Endogenous retinoic acid activity in principal cells and intercalated cells of mouse collecting duct system. PloS One. 2011;6:e16770.

Xu Q, Hendry BM, Maden M, Lu H, Wong YF, Rankin AC, Noor M, Kopp JB. Kidneys of Alb/TGF-beta1 transgenic mice are deficient in retinoic acid and exogenous retinoic acid shows dose-dependent toxicity. Nephron Exp Nephrol. 2010;114:e127-e132.

Hu Q, Noor M, Wong YF, Hylands PJ, Simmonds MSJ, Xu Q, Jiang D, Hendry BM, Xu Q. In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant. 2009; 24:3033-3041.

Xu Q, Norman JT, Shrivastav S, Lucio-Cazana J, Kopp JB. In vitro models of TGF-b1 induced fibrosis suitable for high-throughput screening of anti-fibrotic agents. Am J Physiol Renal Physiol. 2007; 293: F631-F640.

 Alique M, Lucio-Cazana FJ, Moreno V, Xu Q, Konta T, Nakayama K, Furusu A, Sepulveda JC, Kitamura M. Upregulation of cyclooxygenases by retinoic acid in rat mesangial cells. Pharmacology. 2007;79:57-64.

Furusu A, Nakayama K, Xu Q, Konta T, Kitamura M. MAP kinase-dependent, NF-kappaB-independent regulation of inhibitor of apoptosis protein genes by TNF-alpha. J Cell Physiol. 2007;210:703-710.

 Alique M, Moreno V, Kitamura M, Xu Q, Lucio-Cazana FJ. Kinase-dependent, retinoic acid receptor-independent up-regulation of cyclooxygenase-2 by all-trans retinoic acid in human mesangial cells. Br J Pharmacol. 2006; 149:215-25

Xu Q, Konta T, Nakayama K, Furusu A, Moreno-Mazano V, Lucio-Cazana J, Ishikawa Y, Fine LG, Yao J, Kitamura M. Cellular defense against H2O2-induced apoptosis via MAP kinase-MKP-1 pathway. Free Radic Biol Med. 2004; 36: 985-93.

传播推广类文章:

徐启河. 中医药助⼒英国抗疫:机遇与挑战. 英伦⼤叔微信公众号. 2020年5⽉5 ⽇：https://mp.weixin.qq.com/s/VLA02U3yB7FXDB-BqrlT5Q

徐啟河. 中醫藥助⼒英國抗疫:機遇與挑戰. 現代化中醫藥國際協會成⽴⼆⼗週年紀念特刊. 2020 年8 ⽉，pp81-83：https://mcmia.org/wp-content/uploads/2021/12/MCMIA-Album-20.pdf

Xu Q. A Brief History of the GP-TCM RA Newsletters: It all began with the 23 humble “oldsletters”. GP-TCM RA Newsletter, Jan. 2020. http://www.gp-tcm.org/wp-content/uploads/2022/04/Jan-2020-NL-final-R1.pdf

Xu Q. Professor Peter Hylands’ contributions to integrative Chinese medicine. GP-TCM RA Newsletter, Oct. 2019. http://www.gp-tcm.org/wp-content/uploads/2022/04/October-2019-GP-TCM-RA-NL.pdf

Xu Q. Let traditional wisdom inspire: a nephrologist’s view. GP-TCM RA Newsletter, Aug. 2019 http://www.gp-tcm.org/wp-content/uploads/2022/04/August-2019-GP-TCM-RA-NL.pdf

Xu Q. In memoriam Peter John Hylands (1946-2019). GP-TCM RA Newsletter, Jun. 2019 http://www.gp-tcm.org/wp-content/uploads/2022/04/Jun-2019-GP-TCM-RA-NL.pdf

Holden F, Amin V, Kuek D, Kopp JB, Hendry BM and Xu Q. Taming the fire of nephrotoxic botanicals. GP-TCM RA Newsletter, Mar. 2019. http://www.gp-tcm.org/wp-content/uploads/2019/03/Mar-2019-GP-TCM-RA-NL.pdf

Xu Q, Hylands PJ. Integrative Chinese Medicine. GP-TCM RA Newsletter, Apr. 2017. http://www.gp-tcm.org/wp-content/uploads/2022/04/GP-TCM-RA-NL-28-3-2017-compressed.pdf

Xu Q, Duez P, Chang YS. Our Journey Continues: Welcome to the GP-TCM RA Newsletters! GP-TCM RA Newsletter, Mar 2017. http://www.gp-tcm.org/wp-content/uploads/2022/04/Feb-Mar-2017-GP-TCM-RA-NL.pdf

Fan TP, Xu Q. Looking Forward to the Future of the GP-TCM RA. GP-TCM RA Newsletter, Dec. 2016. http://www.gp-tcm.org/wp-content/uploads/2022/04/NL-Christmas-2016-v6.pdf

 Xu Q. Simple and passionate. GP-TCM RA Newsletter, Nov. 2014. http://www.gp-tcm.org/wp-content/uploads/2022/04/November-2014-NL-v4.pdf

徐启河. 伦敦⼤学学院中国学⽣学者联合会举⾏中医在英国学术研讨会. ⼈民⽇报海外版 2000-8-21-第三版.

其它传播推广类活动:

徐启河. 中草药相关的国际标准、规范与指南. 世界传统医药论坛学术讲座. 2023-6-25

孟凡毅、赵凯存、徐启河. 谈中药的毒性与预防. 英伦杏林医话第25 期. 2023-4-28：

https://www.bilibili.com/video/BV1UV4y1R7fW/?vd_source=3a0871eaade596f6b755a1c0c962346a

唐铁军、徐启河、王娴. 中西医能否结合？怎样结合？ 英伦杏林医话第12期。2022-2-26:

https://m.bilibili.com/video/BV1TP4y1c7sk

The PKD Charity UK published a blog introducing Dr Qihe Xu’s research that first uncovers a link between vitamin A and polycystic kidney disease, 18th August 2021: https://pkdcharity.org.uk/news-events/blogs/44-research-uncovers-links-betweenvitamin-a-and-arpkd

2020 KCL news, 14th Dec. 2020, entitled “King’s academic awarded for significant contribution to Chinese medicine”:

https://www.kcl.ac.uk/news/kings-academic-awarded-for-significant-contribution-to-chinese-medicine

MEDshadow 2019: Dr Qihe Xu’s views were cited in an article by Laura Broadwell, entitled Can Chinese Herbs Reduce Need for Rx Meds? https://medshadow.org/can-chinese-herbs-reduce-need-for-rx-meds/

Dr Qihe Xu’s interviewed by CNN in an article, published on 21st June 2019 entitled “Chinese medicine: The next step in cancer recovery?” https://edition.cnn.com/2019/06/19/health/chinese-modern-medicine-cancer-hong-kong-intl/index.html

Kidney Research UK press release by Maria Thompson: “Researchers call for international collaboration to prevent kidney injury caused by plant-based drugs or food”. 17th June 2019: https://www.kidneyresearchuk.org/2019/06/17/researchers-call-for-international-collaboration-to-prevent-kidney-injury-caused-by-plant-based-drugs-or-food

KCL press release by Hannah Forrest: “Researchers call for international collaboration to prevent kidney injury caused by botanicals”, 2019: https://www.kcl.ac.uk/news/researchers-call-for-international-collaboration-to-prevent-kidney-injury-caused-by-botanicals

KCL press release on Dr Qihe Xu’s Science special feature article on the importance of the double-edged sword effect of botanicals in the prevention and treatment of fibrotic diseases (published on 19th December 2014 via numerous public media such as SciGuru.org, medicalxpress.com, myscience.org.uk, topnews-uk.com, cn.biodips.com, ewww.scicentral.com, as well as the homepages of King’s and the University of London): https://medicalxpress.com/news/2014-12-botanicals.html; https://www.myscience.uk/news/2014/the_hunt_for_botanicals-2014-kcl

Dr Qihe Xu was interviewed by The Wall Street Journal on 30th October 2014. The report was published on 3rd November 2014, entitled A Push to Back Traditional Chinese Medicine with More Data: https://www.wsj.com/articles/a-push-to-back-traditional-chinese-medicine-with-more-data-1415036616

Also reported by Fox News:

https://www.foxnews.com/health/researchers-push-to-back-traditional-chinese-medicine-with-more-data

GP-TCM a success, says Brussels, 2013 : https://www.cambridgenetwork.co.uk/news/chinese-medicine-research-programme-confirmed-success-brussels

https://www.manufacturingchemist.com/chinese-medicine-research-programme-a-success-says-brussels-92322

https://globalregulatoryservices.com/news/chinese-medicine-research-programme-confirmed-a-success-by-brussels

https://kipdf.com/congratulations-gp-tcm_5afd6dfe8ead0e314d8b4619.html

Modern medicine can learn from traditional practices, says European Commission, 2012: https://cordis.europa.eu/article/id/91212-modern-medicine-can-learn-from-traditional-practices

凤凰卫视欧洲台报道欧盟第七框架计划《后基因组时代传统中医药研究的良好实践》胜利结题、《中医药规范研究学会》成立 Phoenix TV on the FP7 GP-TCM project, its Final Conference and Congress, as well as the newly founded GP-TCM Research Association, 2012: http://www.youtube.com/watch?v=kQ4QJRfLmqk&feature=youtube_gdata_player

AsianScientist (Apr. 18, 2012) – Scientists from Europe and China have officially launched a new association to research traditional Chinese medicines (TCM). https://www.asianscientist.com/2012/04/topnews/gp-tcm-association-2012

Press release of the European Commission: EU-Sino study spotlights traditional Chinese medicine, 2011: https://cordis.europa.eu/article/id/36108-harmonising-eu-research-on-traditional-chinese-medicines

特邀演讲与交流:

2025

  • Invited keynote speech: Xu Q. Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. Dutch Traditional Chinese Medicine Congress “Building Bridges – The Path to Integrative Medicine”, the Dutch Traditional Chinese Medicine Association Zhong (also known in Dutch as NVTCG ZHONG), The Netherlands, 1st-2nd November 2025.

2024

  • Keynote speech: Xu Q. Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. Chinese Acupuncture and Herbal Medicine Alliance Annual Meeting, Heathrow, UK. 17th November 2024.
  • Keynote speech, international meeting: Xu Q. International Standards & Guidelines in Integrative Medicine Research & Development. The Fourth International Forum of Integrative Medicine in Nephrology and Andrology (IMNA) on Clinical Research and Transformation of Traditional Chinese Medicine, Beijing, China, 26th October 2024
  • Invited talk: Xu Q. Fibrometabolism: Targeting metabolism to develop safe and cost-effective antifibrotics. School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, 25th October 2024.
  • Invited talk: Xu Q. Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. School of Pharmacy, Beijing University of Chinese Medicine, Beijing, China, 24th October 2024.
  • Keynote speech, international meeting: Xu Q. The Quest for Modernisation of Chinese Medicine: International Standards and Guidelines in the Era of Digital Intelligence. Mianyang, Sichuan, China, 1st June. 2024.
  • Invited talk: Xu Q. Towards scarless repair: Fibrosis is a metabolic disorder that could be prevented by metabolic intervention. Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China, 20th June. 2024.

2023               

  • Keynote speech, international meeting: Xu Q. International Guidelines in Traditional Medicine Research: Opportunities & Challenges in Real-World Studies. Bo’ao Summit on Real-World Studies. Bo’ao, Hainan, China, 31st Oct. 2023.
  • Keynote speech, international meeting: Xu Q. Harmony without being uniform: International Guidelines & Standards in R&D of Traditional Medicine. Chinese Medicine and Human Health Conference, London, UK, 7-8th Oct. 2023.
  • Invited talk, international meeting: Xu Q. Proteomics enables a systems view on TGF-β1-induced fibrogenesis and the pharmacology & toxicology of herbal antifibrotics. The 11th Annual Meeting of the GP-TCM Research Association, Leiden, The Netherlands, 18th Sept. 2023.
  • Invited talk, international meeting: Xu Q. International Good Practice Guidelines & Standards Pertinent to Traditional Medicine Research. 2023 China APEC Cooperation Fund International Symposium. Regulatory Science & International Sharing of TM S&T Innovation. Beijing, China, 5th July 2023.
  • Invited talk: Xu Q. Let there be light: Let TCM wisdom inspire modern nephrology & pharmacology. Institute of Integrated Chinese & Western Medicine, Shanghai University of Traditional Chinese Medicine, 13th April 2023.
  • Invited talk, international meeting: Xu Q. Proteomics enables a systems view on fibrogenesis and reveals novel mechanisms of herbal antifibrotics. The 1st International Network Pharmacology Conference and the 2023 Summit of the Network Pharmacology Specialty Committee, World Federation of Chinese Medicine Societies, Huangshan, Hubei, China, 1st April.
  • Invited lecture to undergraduate students: Xu Q. The importance of herbal medicine in a globalised world: Chinese herbal medicine as an example. School of Chinese Pharmacy, Beijing University of Chinese Medicine.  30th March
  • Invited lecture to undergraduate students: Xu Q. Chinese herbal medicine: A herbal journey with a nephrologist. School of Chinese Pharmacy, Beijing University of Chinese Medicine.  30th March
  • Invited talk to faculty members: International Good Practice Guidelines and Standards in Research & Development of Herbal Medicine. School of Chinese Pharmacy, Beijing University of Chinese Medicine.  29th March

2022               

  • Invited talk: Xu Q. Proteomics enables a systems view on fibrogenesis and reveals novel mechanisms of herbal antifibrotics. The 6th Conference of the Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine Societies, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 11th January.

2021               

  • Invited talk: Xu Q. Taming the Fire of Nephrotoxic Botanicals. The Specialty Committee of Research on Safety of Clinical Use of Drugs, World Federation of Chinese Medicine Societies, Shenzhen, China, 7th August 2021.

2019 

  • Invited talk: Xu Q. Three decades of studies in the East & the West: Stay hungry, stay young. Xinxiang Medical University, Xinxiang, Henan, China, 18th October 2019.
  • Invited talk: Xu Q. Traditional Chinese Medicine for the Prevention and Treatment of Acute Kidney Injury: State of the Art and Frontiers. Panel 6, TCM for Critical Diseases. The 6th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 21-22 October.
  • Invited talk: Xu Q. Integrative Chinese Medicine Research of Weakening Kidney and Kidney-tonic Therapies. School of Chinese Medicine, Hong Kong Baptist University, 26th September 2019.
  • Invited talk: Xu Q. How TCM could inspire ground-breaking discoveries in modern medicine: A nephrologist point of view. Seminar on Research and Development of Chinese Medicines 2019, Committee on Research and Development of Chinese Medicine, Innovation and Technology Commission, Central Government Offices, Hong Kong, China, 24th September.
  • Invited talk: Xu Q. The Defensive Role for the Collecting Duct and Its Role in AKI and CKD. World Association of Chinese Renal Physicians, Qingdao, Shandong, China, 22nd September 2019.
  • Invited talk: Xu Q. Taming the Fire of Nephrotoxic Botanicals. Pharmacology & Toxicology session, the 7th Annual Meeting of the GP-TCM Research Association, Daegu, South Korea, 9th July 2019
  • Invited lecture: Xu Q. Integrating wisdom from West and East, to identify key blind spots and frontiers in modern nephrology research. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China, 4th July 2019.
  • Invited talk: Xu Q. Let there be light: Let TCM wisdom inspire modern nephrology. World Summit of Chinese Medicine, Shenzhen, 29th June-1st July 2019.
  • Invited special session organiser and leading speaker: Xu Q. The collecting duct: A critical protector against renal tubulointerstitial injury? UK Kidney Week 2019, Brighton, 3-5 June 2019
  • Invited lecture: Xu Q. Let there be light: Let TCM wisdom inspire modern nephrology. Institute of Clinical Research, Japan-China Friendship Hospital, Beijing, 18th April 2019.
  • Invited lecture: Xu Q. Let there be light: Let TCM wisdom inspire modern nephrology. Department of Nephrology, Japan-China Friendship Hospital, Beijing, 18th April 2019.
  • Invited lecture: Xu Q. Focusing on A Major Blindspot in Modern Nephrology and Strive for a New Era in the Prevention and Treatment of AKI and CKD. School of Chinese Medicine, Beijing University of Chinese Medicine. 2nd April 2019.
  • Workshop with undergraduates: Xu Q. Let’s Flourish at Each Stage of Our Lives. School of Pharmacy, Beijing University of Chinese Medicine. 1st April 2019.
  • Invited lecture: Xu Q. Traditional Chinese Medicine for the Prevention and Treatment of Acute Kidney Injury: Where are we? We are we going? School of Pharmacy, Beijing University of Chinese Medicine. 1st April 2019.

2018               

  • Keynote speech:  Xu Q. Traditional Chinese Medicine for Acute Kidney Injury. The 19th International Congress of Oriental Medicine, International Convention Centre of National Taiwan University Hospital, Taipei, Taiwan, 24th-26th November 2018.
  • Invited speaker: Xu Q. Efficacy- and omics-based research of anti-fibrotic Chinese herbal medicines. International Forum on Chinese Medicine Hong Kong Summit, Hong Kong International Convention & Exhibition Centre, Hong Kong, China, 5th August 2018.
  • Xu Q. Defining a principal renal defender: Collecting ducts and its retinoic acid signalling. School of Medicine, Aberdeen University, Scotland, UK, 17 August 2018.
  • Xu Q. Proteomics of Fibrosis and Antifibrotics. Henan University of Science & Technology, Luoyang, Henan, China. 29th March 2018.
  • Xu Q. The Making of Steel: MBBS education and training of medical professionals in the UK. Luohe Medical School, Henan, China. 22nd March 2018.
  • Xu Q. AKI & CKD: The Blind Spots and Research Directions. A Lecture for Members of Faculty and MBBS students. Luohe Medical School, Henan, China. 22nd March 2018.
  • Xu Q. Brilliance Comes from Every Stage of Life: A Lecture for MBBS students. Luohe Medical School, Henan, China. 22nd March 2018.
  • Xu Q. Proteomics of Fibrosis and Antifibrotics. School of Pharmacy, Beijing University of Chinese Medicine. 21st March

2017

  • Keynote speech:  Xu Q. Efficacy- and proteomics-based research of anti-fibrotic Chinese herbal medicines. Association of Tradition Chinese Medicine & Acupuncture UK, London, 29 October 2017.
  • Xu Q. How to deal with nephrotoxicity in TCM? The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.
  • Xu Q. An Annual Report of the UKCGCM. The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.
  • Xu Q. A Secretomic Study of TGF-beta-induced Fibrogenesis and the Anti-fibrotic Effects of Scutelariae Radix and Baicalein. The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.
  • Keynote speech:  Xu Q. The quest for modernisation of traditional Chinese medicine: A global view on quality and standardisation. The International Conference on Quality and Efficacy of Chinese Medicine, Shiyan, Hubei, August 2017 (invited international plenary)
  • Xu Q. Retinoic acid signalling: Central regulator of renal defences? An invited talk at Xiangyang Hospital, Hubei, August 2017.
  • Xu Q. King’s CICM and the hunt for antifibrotics. An invited talk at Hubei University of TCM, Hubei, August 2017.

2016               

  • Keynote speech: Xu Q. Chinese materia medica: A reflection on what we have learnt from the EU’s FP7 GP-TCM Project. Panel 3, The 5th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 24-25 October.
  • Keynote speech: Xu Q. Use science to explore tradition; use tradition to tackle fibrosis. Panel 8, The 5th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 24-25 October.

2015               

  • Xu Q. The quest for modernisation of traditional Chinese medicine: A global view from Europe. KCL Pharmacology Society, King’s College London, 2nd November.
  • Keynote speech:  Xu Q. The quest for modernisation of traditional Chinese medicine: Focus on good practices and quality. The Launch Conference of the Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine Societies, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 25th October
  • Keynote speech:  Xu Q. Herbal Medicines for Acute Kidney Injury: Evidence, Gaps and Frontiers. The 12th Consortium for Globalisation of Chinese Medicine Annual Meeting, London, Ontario, Canada, August 2015.
  • Xu Q. The quest for modernisation of traditional Chinese medicine: A global view from Europe. School of Pharmacy, China Medical University, Taichung, Taiwan, 10th April.
  • Xu Q. King’s Centre for Integrative Chinese Medicine & its research on anti- and pro-fibrotic botanicals. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Institute of Traditional Medicine, National Yang-Ming University, Taiwan, 8th April.
  • Xu Q. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era under European Union’s Seventh Framework Programme. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Institute of Traditional Medicine, National Yang-Ming University, Taiwan, 8th April.
  • Xu Q. Retinoic acid signalling: A master regulator of renal defences. School of Pharmacy, Beijing University of Chinese Medicine. 27th March.

2014               

  • Xu Q. TCM knowledge-based discovery of antifibrotics. The 3rd Annual Meeting of GP-TCM RA, Nanjing, China, 18th July.
  • Xu Q. Hunting for antifibrotics. PuraPharm, Nanning, China, 16th July.
  • Xu Q. Vitamin A, the Kidney and Kidney Diseases. Chengdu University of TCM Affiliated Hospital, Chengdu, China, 15th July.
  • Xu Q. Hunting for antifibrotics. Chengdu University of TCM, Chengdu, China, 14th July.
  • Xu Q. What have we learnt from GP-TCM, the EU’s 1st EU-China Collaboration under its Seventh Framework Programme? The Southwest Daodi Chinese Medica Innovation 2011 Project, Chengdu, China, 13th July.
  • Xu Q. King’s Centre for Integrative Chinese Medicine and Our Research on Anti- and Pro-fibrotic Herbs. Beijing University of Traditional Chinese Medicine, 2nd April.
  • Xu Q. On TCM – Some Updates from Europe. Beijing University of Traditional Chinese Medicine, 2nd April.

2013               

  • Xu Q. Panellist talk entitled King’s Centre for Integrative Chinese Medicine. Interregional Collaborations in Industry and Academia Session, Consortium for Globalization of Chinese Medicine Meeting, Graz, Austria, 27th August.
  • Xu Q. Why am I here? The Herbal Journey of a Nephrologist. International symposium on medicinal plants and quality control, Brussels, Belgium, on the 23rd-24th May.

2012               

  • Xu Q.  What have we learnt from the EU’s first Coordination Action on TCM Research? Shanghai International Traditional Chinese Medicine Conference and the 1st GP-TCM Research Association Annual Meeting, 20th-21st October, Shanghai, China.
  • Xu Q. From anti-fibrotic Chinese herbs to GP-TCM, the first EU-China collaboration on modernisation of Traditional Chinese Medicine (TCM). Chengdu University of TCM, 16th October, Chengdu, China.
  • Xu Q. From anti-fibrotic Chinese herbs to EU’s first Coordination Action on TCM Research. China-Japan Friendship Hospital, 27th August, Beijing, China.
  • Xu Q. From anti-fibrotic Chinese herbs to GP-TCM, the first EU-China collaboration on modernisation of Traditional Chinese Medicine (TCM). National Engineering Research Centre for Modernisation of TCM, 24th August, Zhuhai, China.
  • Xu Q. Discovery and rediscovery of anti-fibrotic Chinese herbal medicines. CGCM Annual Conference, 22nd August, Macao, China.
  • Xu Q. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. CGCM Annual Conference, 21st August, Macao, China.
  • Xu Q. From anti-fibrotic herbs to GP-TCM. Northwest University. 15th August, Xi’an, China.
  • Xu Q. Retinoic acid and the kidney: Focus on target genes. The Vitamins Workshop, 11th June, Guy’s Hospital, London, UK.
  • Xu Q. Target genes of endogenous retinoic acid and retinoic acid receptors in collecting duct cells: a pan-genomic view. Southwest and East Kidney Society (SWEKS) Annual Meeting, 25th April, Warren House, Kingston-Upon-Thames, UK.
  • Xu Q.  Concluding remarks: Integrity, Integration and Innovation. The GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.
  • Xu Q.  An introduction to The FP7 GP-TCM Project. Set the Scene: Roadmap to Evidence-Based TCM. The GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.
  • Xu Q. The GP-TCM Research Association. The GP-TCM Final Conference. 12th-13th April, Rolduc, Kerkrade, the Netherlands.
  • Xu Q. Key renal target genes of retinoid system. 30th March, Comprehensive Biomedical Research Centre, King’s College London, UK.

2011

  • Xu Q. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. The Association of Traditional Chinese Medicine (UK) Annual Meeting, Middlesex University, Hendon, London, November 2011.
  • Xu Q. Discovery and rediscovery of anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 2011 Shanghai International Conference on TCM and Natural Medicine. October 2011. The talk was invited by the organizing committee and kindly sponsored by the British Consulate General based in Shanghai, China, with funding provided by The Department for Business, Innovation and Skills (BIS), United Kingdom.
  • Xu Q. In vitro models of fibrosis suitable for high-throughput screening and discovery of anti-fibrotic and pro-fibrotic herbal entities. Department of Biomedical Science, The School of Life Sciences, University of Westminster, London, UK, October 2011.
  • Uzuner H, Xu Q. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. The 8th World Congress of Chinese Medicine, Westminster Central Hall, London, September 2011.
  • Xu Q. TCM knowledge-based discovery and rediscovery of in vitro anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 8th World Congress of Chinese Medicine, Westminster Central Hall, London, September 2011 (Plenary speech)
  • Xu Q. Knowledge-based discovery and re-discovery of in vitro anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 8th Congress of Consortium for Globalisation of Chinese Medicine. Shanghai, August 2011. (Panellist speech)
  • Xu Q. What does TCM industry needs and what academia can offer? The 8th Congress of Consortium for Globalisation of Chinese Medicine. Shanghai, August 2011. (Panellist speech)
  • Xu Q. Training EU scientist towards good practice in complex herbal product research: A FP7 Marie Curie grant revision discussion. The 2nd Annual Meeting of the GP-TCM Consortium. University of Minho, Braga, Portugal, July 2011.
  • Xu Q. “The New Society”. The 2nd Annual Meeting of the GP-TCM Consortium. University of Minho, Braga, Portugal, July 2011.
  • Xu Q. Biological activity and target genes for endogenous retinoic acid in mouse kidney cells. MRC Centre for Transplantation. KCL, London, UK, July 2011.
  • Xu Q. Target genes for endogenous retinoic acid in mouse collecting duct cells. 15th European Nephrogenesis Workshop. Institute of Child Health, UCL, London, UK, May 2011.
  • Xu Q. In vitro models of fibrosis, anti-fibrotic herbs and the GP-TCM and TEST-GP Consortia on modernisation of Chinese medicine. Hainan Medical College, China (April 2011); Xinxiang Medical University, China (May 2011).
  • Xu Q. TGF-beta and retinoids: Crosstalk in development, immunity and tissue repair. The Frisk Seminar Room Presentation Series. King’s College London, March 2011.
  • Xu Q. A tale of a KRUK-sponsored research project on anti-fibrotic herbs. Kidney Research UK fundraising event at Leeds Castle, UK, March 2011.
  • Xu Q. The roles for activated vitamin A in kidneys before and after birth. James Black Centre Seminar Series, King’s College London, Feb. 2011.

2010               

  • Xu Q. Training EU scientists towards good practice in TCM research: A FP7 Marie Curie grants revision discussion. The 1st Annual Meeting of the GP-TCM Consortium. Henley Business School, Henley-Upon-Thames, UK, July 2010.
  • Xu Q. A new TCM research society of Europe. The 1st Annual Meeting of the GP-TCM Consortium. Henley Business School, Henley-Upon-Thames, UK, July 2010.
  • Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. University of Hong Kong (HKU). The trip was kindly sponsored by the KCL-HKU partnership fund.
  • Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. University of Macau (UM). The trip was kindly sponsored by the KCL-HKU partnership fund and UM.

2009               

  • Wong YF, Kopp JB, Roberts C, Maden M, Scambler PJ, Rankin AC, Dutt N, Noor M, Hendry BM, Xu Q. Physiological retinoic acid activity in the collecting ducts of postnatal mouse kidneys. American Society of Nephrology Annual Meeting and Renal Week. San Diego, CA, October 2009 (presented by WYF)
  • Xu Q. Good Practice of Chinese Medicine Research in the Post-genomic Era. The 8th CGCM Conference, Nottingham, August 2009.
  • Hu Q, Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. The James Black Centre Seminar Series. KCL, London, UK, Feb. 2009. (Presented by HQ and XQ)
  • Hu Q, Hendry BM, Xu Q. Discovery of herbal medicines with in vitro anti-fibrotic activities. Keystone Symposia: Fibrosis. Keystone, Colorado, Jan. 2009 (Presented by XQ).
  • Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. The General Hospital of Chinese PLA, Beijing, Jan. 2009.
  • Xu Q. GP-TCM: Its Mission, Strength and Weakness. The Sino-EU GP-TCM Workshop, Beijing.

2008             

  • Xu Q.  From anti-fibrotic herbs to GP-TCM, a FP7 Consortium on Chinese medicine research. The Annual Meeting of the Chinese Life Scientists Society in the UK. Oxford, UK.
  • Xu Q. Discovery of herbs with in vitro anti-scarring activities. Traditional Chinese Medicine Week UK, Royal Society of Medicine, London, UK

2007

  • Xu Q. Searching for Antifibrotics from herbs. The Annual General Meeting of The Association of Traditional Chinese Medicine (UK), University of Westminster, London.
  • Xu Q. Searching for Antifibrotics. Sir James Black Centre, KCL.
  • Xu Q. In vitro models of fibrosis for screening anti-fibrotic activities. 13th Meeting of the Chinese Life Scientists Society in the UK, Cambridge, UK.
  • Xu Q. High-throughput screening of anti-fibrotic drugs. Teleconference with the FibroGen.
  • Xu Q. Antifibrotic activities of herbal medicines: To be revisited using in vitro models of fibrosis. Meeting with Phynova senior scientists at KCL, June.
  • Xu Q. Searching for antifibrotics. Renovo, Manchester, UK, June.
  • Xu Q. In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of anti-fibrotic agents. Keystone Symposia. Molecular Mechanisms of Fibrosis: From Bench to Bedside. Tahoe City, CA, March 2007.
  • Xu Q. In vitro models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Teleconference with the Novartis Horsham Research Centre
  • Xu Q. Searching for antifibrotics: In vitro models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Xinxiang Medical University, Henan, China; Zheng Zhou University (ZZU), Henan, China; Peking University First Hospital, Beijing, China; Beijing University of Chinese Medicine, Beijing, China.
  • Xu Q. In vitro models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Annual Meeting of the Chinese Society of Nephrology, Xiamen, China.
  • Xu Q. Retinoid system in health and diseases of the kidney. Institute of Child Health, UCL, London.
  • Xu Q. In vitro models of fibrosis for anti-fibrotic drug development. St Helier’s Southwest Thames Renal & Transplantation Unit, London.

2005               

  • Xu Q. TGF-beta, CTGF and Fibrosis. Kidney Disease Section, NIDDK, NIH, Bethesda,  Maryland, USA.
  • Xu Q. Retinoids, Immunity and Systemic Lupus Erythematosus. Kidney Disease Section, NIDDK, NIH, Bethesda, MD, USA.
  • Xu Q. The Retinoid system: Central protective machinery against tissue injury? Kidney Disease Section, NIDDK, NIH, Bethesda, MD, USA.
  • Xu Q. Retinoids in Nephrology:  Promises and pitfalls.  PLA Postgraduate School of Medicine, Beijing, China.
  • Xu Q. Towards understanding the anti-NFkB activity of retinoid: Establishing a biosensor system in rat mesangial cells. PLA Postgraduate School of Medicine, Beijing, China.
  • Xu Q. Retinoid treatment of nephritides: Encouraging experimental data and challenging hypotheses. The 1st Affiliated Hospital, Xinxiang Medical College, Henan, China.

2003               

  • Xu Q. Retinoids in nephrology: Promises and potential limitations. The 10th Annual Meeting of the Chinese Life Scientists Society in the UK, Oxford.
  • Xu Q. Transcriptional induction of MKP-1 by retinoids: Involvement of different nuclear receptors and role in the anti-apoptotic effect of retinoic acid. The 9th Annual Meeting of the Chinese Life Scientists Society in the UK, London.